ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013

  ArQule to Report Second Quarter 2013 Financial Results on July 30, 2013

Business Wire

WOBURN, Mass. -- July 23, 2013

ArQule, Inc. (NASDAQ: ARQL) today announced that it will report its financial
results for the second quarter of 2013 on Tuesday, July 30, 2013 at 7:00 a.m.
Eastern Time. The Company will hold a conference call at 9:00 a.m. Eastern
Time that day to discuss these results.

Conference Call and Webcast      
Date:                                   Tuesday, July 30, 2013
Time:                                   9:00 a.m., Eastern Time
                                        
Conference Call Numbers
Domestic (toll free):                   (877) 868-1831
International:                          (914) 495-8595
Webcast:                                www.arqule.com

A replay of the conference call will be available beginning two hours after
the completion of the call through August 1, 2013 and can be accessed by
dialing toll-free 855-859-2056 and outside the U.S. 404-537-3406. The
confirmation code for replayed calls is 19175389.

About ArQule

ArQule is a biotechnology company engaged in the research and development of
next-generation, small-molecule cancer therapeutics. The Company’s targeted,
broad-spectrum products and research programs are focused on key biological
processes that are central to human cancers. ArQule’s lead product, in Phase 2
and Phase 3 clinical development, is tivantinib (ARQ 197), an oral, selective
inhibitor of the c-MET receptor tyrosine kinase. The Company’s pipeline
includes: ARQ 092, designed to inhibit the AKT serine/threonine kinase; ARQ
087, designed to inhibit fibroblast growth factor receptor (FGFR); ARQ 621,
designed to inhibit the Eg5 kinesin motor protein; and ARQ 736, designed to
inhibit the RAF kinases. ArQule’s current discovery efforts, which are based
on the ArQule Kinase Inhibitor Platform (AKIP™), are focused on the
identification of novel kinase inhibitors that are potent, selective and do
not compete with ATP (adenosine triphosphate) for binding to the kinase.

Contact:

ArQule, Inc.
William B. Boni, 781-994-0300
VP, Investor Relations/
Corp. Communications
www.ArQule.com